The effects of the in vivo treatment with a mAb (DB-1) that neutralizes mouse IFN-gamma on the development of the SLE-like syndrome in MRL/1pr-1pr (MRL-1pr) mice were studied. The results show that the i.p. administration of 2.6 mg/week of DB-1 from the 12th to the 20th week of age neither affected the survival nor the incidence and severity of lupus nephritis in MRL-1pr mice. This study argues against the pathogenic relevance of IFN-gamma in this experimental model of human SLE.
INVIVO TREATMENT WITH A MONOCLONAL-ANTIBODY TO INTERFERON-GAMMA NEITHER AFFECTS THE SURVIVAL NOR THE INCIDENCE OF LUPUS-NEPHRITIS IN THE MRL/LPR-LPR MOUSE
NICOLETTI, FERDINANDO;
1992-01-01
Abstract
The effects of the in vivo treatment with a mAb (DB-1) that neutralizes mouse IFN-gamma on the development of the SLE-like syndrome in MRL/1pr-1pr (MRL-1pr) mice were studied. The results show that the i.p. administration of 2.6 mg/week of DB-1 from the 12th to the 20th week of age neither affected the survival nor the incidence and severity of lupus nephritis in MRL-1pr mice. This study argues against the pathogenic relevance of IFN-gamma in this experimental model of human SLE.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
